Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Cipla
Julphar
Express Scripts
Teva
Boehringer Ingelheim
Fish and Richardson
US Department of Justice
Citi
Medtronic

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,407,943

« Back to Dashboard

Summary for Patent: 7,407,943
Title:Antisense modulation of apolipoprotein B expression
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
Inventor(s): Crooke; Rosanne M. (Carlsbad, CA), Graham; Mark J. (San Clemente, CA)
Assignee: ISIS Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:10/147,196
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,407,943

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,407,943

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE44760 Antisense modulation of apolipoprotein B-expression ➤ Subscribe
7,511,131 Antisense modulation of apolipoprotein B expression ➤ Subscribe
7,803,930 Antisense modulation of apolipoprotein B-expression ➤ Subscribe
8,735,364 Antisense modulation of apolipoprotein B expression ➤ Subscribe
7,888,324 Antisense modulation of apolipoprotein B expression ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,407,943

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2336318 ➤ Subscribe
Slovenia 1569695 ➤ Subscribe
Portugal 2336318 ➤ Subscribe
Portugal 2174945 ➤ Subscribe
Portugal 1569695 ➤ Subscribe
Japan 2017176193 ➤ Subscribe
Japan 2017127311 ➤ Subscribe
Japan 2016005481 ➤ Subscribe
Japan 2015198669 ➤ Subscribe
Japan 2013066488 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
US Department of Justice
Merck
Cipla
Cerilliant
Harvard Business School
US Army
Medtronic
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot